SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-QSB
[ x ] Quarterly report under Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the quarterly period ended: June 30, 2000
[ ] Transition report under Section 13 or 15(d) of the Exchange Act
For the transition period from _____________ to _______________
Commission file number: 0-22865
-------
AMERIMMUNE PHARMACEUTICALS, INC.
--------------------------------------------------------------------------
(Exact Name of Small Business Issuer as Specified in Its Charter)
Colorado 84-1044910
-------------------------------------- --------------------------------
(State or Other Jurisdiction of (IRS Employer
Incorporation or Organization) Identification No.)
21550 Oxnard Street, Suite 830 * Woodland Hills, California 91367
--------------------------------------------------------------------------
(Address of Principal Executive Offices)
(818)676-0404
--------------------------------------------------------------------------
(Issuer's Telephone Number, Including Area Code)
--------------------------------------------------------------------------
(Former Name, Former Address and Former Fiscal Year,
if Changed Since Last Report)
Check whether the issuer: (1) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past
90 days.
Yes X No
------- -------
State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date: AS OF JULY 31, 2000,
43,042,856 SHARES OF THE ISSUER'S COMMON STOCK, $0.05 PAR VALUE PER SHARE,
WERE OUTSTANDING.
Transitional Small Business Disclosure Format (check one):
Yes No X
------- -------
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
PART I FINANCIAL INFORMATION PAGE NO.
Item 1. Financial Statements:
Consolidated Balance Sheets - March 31, 2000 and
June 30, 2000 (unaudited). . . . . . . . . . . . . . . . . . . . . . . .2
Consolidated Statements of Operations - for the Three Months Ended
June 30, 1999 and 2000 and cumulative amounts from inception
through June 30, 2000 (unaudited). . . . . . . . . . . . . . . . . . . .3
Consolidated Statements of Cash Flows - for the Three Months
Ended June 30, 1999 and 2000 and cumulative amounts from
inception through June 30, 2000 (unaudited). . . . . . . . . . . . . . .4
Notes to Unaudited Consolidated Financial Statements . . . . . . . . . .6
Item 2. Management's Discussion and Analysis or Plan
of Operation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
PART II OTHER INFORMATION
Item 1. Legal Proceedings. . . . . . . . . . . . . . . . . . . . . . . 15
Item 6. Exhibits and Reports on Form 8-K . . . . . . . . . . . . . . . 15
Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
PART I (A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED BALANCE SHEETS
ITEM 1. FINANCIAL STATEMENTS
ASSETS
<TABLE>
<CAPTION>
MARCH 31, 2000 JUNE 30, 2000
CURRENT ASSETS (AUDITED) (UNAUDITED)
-------------- --------------
<S> <C> <C>
Cash and cash equivalents $ 522,649 $ 842,716
Marketable securities 618,360 -
Other current assets 37,926 28,032
------------ ------------
TOTAL CURRENT ASSETS 1,178,935 870,748
------------ ------------
PROPERTY AND EQUIPMENT, NET 23,475 20,530
------------ ------------
OTHER ASSETS
Deposits 3,040 3,040
------------ ------------
TOTAL ASSETS $ 1,205,450 $ 894,318
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $ 83,242 $ 36,931
Accrued liabilities 141,897 156,472
------------ ------------
TOTAL CURRENT LIABILITIES 225,139 193,403
------------ ------------
COMMITMENTS AND CONTINGENCIES (Note 3)
SHAREHOLDERS' EQUITY
Preferred stock $0.10 par value, 50,000,000
shares authorized, no shares issued or
outstanding - -
Common stock $0.05 par value, 100,000,000 shares
authorized, 43,042,856 shares issued and
outstanding 2,152,143 2,152,143
Additional paid-in-capital 3,090,266 3,090,266
Note receivable from affiliate (156,989) (160,022)
Deficit accumulated during the development stage (4,105,109) (4,381,472)
------------ ------------
TOTAL SHAREHOLDERS' EQUITY 980,311 700,915
------------ ------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 1,205,450 $ 894,318
============ ============
</TABLE>
See accompanying notes
2
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED JUNE 30, 1999 AND 2000
AND CUMULATIVE AMOUNTS FROM APRIL 10, 1998 (Date of Inception)
THROUGH JUNE 30, 2000
(unaudited)
<TABLE>
<CAPTION>
THREE MONTHS THREE MONTHS CUMULATIVE
ENDED ENDED AMOUNTS FROM
JUNE 30, 1999 JUNE 30, 2000 INCEPTION
------------- ------------- ---------
<S> <C> <C> <C>
COSTS AND EXPENSES
Research and development $ 259,533 $ 119,075 1,373,886
General and administrative 208,534 169,766 3,107,726
------------ ------------ ------------
OPERATING LOSS (468,067) (288,841) (4,481,612)
OTHER INCOME (EXPENSE)
Interest income 25,382 14,967 114,062
Interest expense (583) (889) (9,922)
------------ ------------ ------------
24,799 14,078 104,140
------------ ------------ ------------
LOSS BEFORE PROVISION
FOR INCOME TAXES (443,268) (274,763) (4,377,472)
PROVISION FOR INCOME TAXES 800 (1,600) 4,000
------------ ------------ ------------
NET LOSS $ (444,068) $ (276,363) $ (4,381,472)
============ ============ ============
NET LOSS PER COMMON SHARE - BASIC
AND DILUTED $ (0.01) $ (0.01)
============ ============
WEIGHTED AVERAGE NUMBER OF SHARES
OUTSTANDING - BASIC AND DILUTED 43,042,856 43,042,856
============ ============
</TABLE>
See accompanying notes
3
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 1999 AND 2000
AND CUMULATIVE AMOUNTS FROM APRIL 10, 1998 (Date of Inception)
THROUGH JUNE 30, 2000
(unaudited)
<TABLE>
<CAPTION>
CUMULATIVE
THREE MONTHS THREE MONTHS AMOUNTS
ENDED ENDED FROM
JUNE 30, 1999 JUNE 30, 2000 INCEPTION
------------- ------------- ---------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $ (444,068) $ (276,363) $ (4,381,472)
ADJUSTMENTS TO RECONCILE NET LOSS
TO NET CASH USED BY OPERATING ACTIVITIES
Noncash transactions:
Depreciation and amortization 2,765 2,945 14,545
Fair value of stock and an option issued
in exchange for services and trademark
rights - - 814,000
Fair value of stock issued to prospective
officers - - 142,500
Fair value of stock transferred to a
prospective officer by a principal
shareholder - - 90,000
Fair value of stock and an option
transferred by a principal shareholder
in exchange for services - - 452,000
Fair value of stock options issued in
exchange for services - - 6,163
Modification of stock options - - 383,794
Changes in assets and liabilities:
Advances from/to affiliates 46,581 - -
Other current assets (6,057) 9,894 (28,032)
Prepaid management fees 18,281 - -
Deposits - - (3,040)
Accounts payable and accrued expenses (25,615) (31,736) 193,403
------------ ------------ ------------
Total adjustments 35,955 (18,897) 2,065,333
------------ ------------ ------------
NET CASH USED BY OPERATING ACTIVITIES (408,113) (295,260) (2,316,139)
------------ ------------ ------------
CASH FLOWS FROM INVESTING ACTIVITIES
Sales (Purchases) of marketable securities - 618,360 -
Purchases of property and equipment (2,278) - (35,075)
Loan to an affiliate (100,000) (3,033) (160,022)
------------ ------------ ------------
NET CASH USED IN INVESTING ACTIVITIES (102,278) 615,327 (195,097)
------------ ------------ ------------
</TABLE>
Continued on next page
4
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 1999 AND 2000
AND CUMULATIVE AMOUNTS FROM APRIL 10, 1998 (Date of Inception)
THROUGH JUNE 30, 2000
(unaudited)
<TABLE>
<CAPTION>
<S> <C> <C> <C>
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from sale of common stock - - 3,353,952
------------ ------------ ------------
NET INCREASE (DECREASE) IN CASH AND
CASH EQUIVALENTS (510,391) 320,067 842,716
------------ ------------ ------------
CASH AND CASH EQUIVALENTS,
Beginning of Period 2,614,523 522,649 -
------------ ------------ ------------
CASH AND CASH EQUIVALENTS, Ending of Period $ 2,104,132 $ 842,716 $ 842,716
============ ============ ============
</TABLE>
See accompanying notes
5
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2000
1. BUSINESS AND BASIS OF PRESENTATION
BUSINESS AND ORGANIZATION
Amerimmune Pharmaceuticals, Inc. (the "Company"), formerly named Versailles
Capital Corporation, is a Colorado Corporation incorporated on December 31,
1986. From 1991 through February 22, 1999, the Company was inactive aside
from seeking a business combination candidate.
British Lion Medical, Inc. ("British Lion") was incorporated in California
in August 1997 and commenced operations on April 10, 1998. British Lion
was engaged in the pharmaceutical research business with the primary
purpose of developing Cytolin(R), a drug designed to protect the immune
system, especially in patients suffering from Human Immunodeficiency Virus
("HIV").
On February 17, 1999, the Company, British Lion and Amerimmune, Inc.
("AI"), a newly organized, wholly owned subsidiary of the Company, entered
into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to
the Merger Agreement on February 23, 1999, each share of British Lion's
issued and outstanding no par value common stock (5,853,500 shares) was
exchanged for 7.133978 newly issued shares (41,758,740 shares) of the
Company's $0.05 par value per share common stock. After the exchange,
former British Lion shareholders acquired approximately 97% of the issued
and outstanding voting shares of the Company and the Company acquired all
of the issued and outstanding shares of British Lion through a merger of
British Lion with and into AI, with AI as the surviving legal entity (the
"Transaction"). Prior to the Transaction, the Company had nominal assets
and liabilities. Unless otherwise noted, all references to the number of
shares of common stock in these financial statements are based upon the
equivalent post-exchange number of shares of the Company's common stock.
For financial reporting purposes, the Transaction has been accounted for as
a reverse acquisition whereby British Lion is deemed to have acquired the
Company. Since this was a reverse acquisition, the legal acquiror, the
Company, continued in existence as the legal entity whose shares represent
the outstanding common stock of the combined entities. The acquisition has
been accounted for as a recapitalization of British Lion based upon
historical cost. The recapitalization was given retroactive effect. In
connection with the Transaction, the Company succeeded to the business of
British Lion and became engaged in the pharmaceutical research business
with the primary purpose of developing Cytolin(R). The Company has
assumed the obligations of British Lion including all outstanding stock
options and warrants to purchase shares of British Lion's common stock and
has issued equivalent shares of the Company common stock under the same
terms and conditions.
On August 6, 1999, the shareholders of the Company adopted an amendment to
the Company's articles of incorporation to change the name of the Company
to Amerimmune Pharmaceuticals, Inc. from Versailles Capital Corporation.
6
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2000 (CONTINUED)
BASIS OF PRESENTATION AND MANAGEMENT PLAN
The accompanying consolidated financial statements of the Company have been
prepared in accordance with generally accepted accounting principles for
interim financial statements and with the instructions to Form 10-QSB on
the basis of a going concern. Certain notes and other information have
been condensed or omitted from the interim financial statements presented
in this report. Accordingly, they do not include all of the information
and footnotes required by generally accepted accounting principles for
complete financial statements. In the opinion of management, the financial
statements reflect all adjustments considered necessary for a fair
presentation. The results of operations for the three months ended June
30, 2000 are not necessarily indicative of the results to be expected for
the full year. For further information, refer to the financial statements
and footnotes thereto included in the Company's Annual Report on Form 10-KSB
for the period ended March 31, 2000 as filed with the Securities and
Exchange Commission. All significant intercompany balances and
transactions have been eliminated in consolidation.
The Company is a development stage pharmaceutical research company and has
not generated any revenues from operations for the period from April 10,
1998 (the date that British Lion commenced operations) through June 30,
2000. The Company has devoted substantially all of its resources to the
acquisition of a license, research and development of Cytolin(R), and
expenses related to the startup of its business. The Company has been
unprofitable since inception and expects to incur substantial additional
operating losses for the next twelve months, as well as for the next few
years, as it increases expenditures on its research and development
activities and allocates significant and increasing resources to clinical
testing, marketing and other activities.
The Company commenced a tolerability study for Cytolin(R) after a clinical
protocol was sanctioned by the Food and Drug Administration ("FDA") and the
bulk drug has been manufactured, tested, packaged, and released for
clinical use. The Company has completed the submission of related
manufacturing records to the FDA.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company estimates that it
will require significant additional funding over the next three years to
continue operations and to successfully complete the FDA approval process
for Cytolin(R). The Company believes that additional funds will be needed
to fund operations after September 30, 2000. The Company has established
plans designed to increase the capitalization of the Company and is
actively seeking additional capital that will provide funds needed to
increase the internal growth of the Company in order to fully implement its
business plans. There can be no assurances that such additional capital
will be available to the Company on favorable terms, if at all. The
failure of the Company to obtain additional funding if and when required
would have a material adverse effect on the Company's ability to fulfill
its business plan, continue its operations and meet its financial commitments.
7
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2000 (CONTINUED)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
CASH AND CASH EQUIVALENTS
The Company considers all highly liquid debt instruments purchased with an
original maturity of three months or less to be cash equivalents.
MARKETABLE SECURITIES
Marketable securities are classified as held-to-maturity and consist of
investments in United States Government Bonds that have maturities over
three months but less than one year from date of purchase.
NET LOSS PER SHARE
Loss per share is presented in accordance with the provisions of Statement
of Financial Accounting Standards No. 128, "Earnings Per Share" ("SFAS
128"), and the Securities and Exchange Commission ("SEC") Staff Accounting
Bulletin No. 98 ("SAB 98"). Basic earnings per share excludes dilution for
common stock equivalents and is computed by dividing income or loss
available to common shareholders by the weighted average number of common
shares outstanding for the period. Diluted earnings per share reflects the
potential dilution that could occur if securities or other contracts to
issue common stock were exercised or converted and resulted in the issuance
of common stock.
Pursuant to SAB 98, common stock issued for nominal consideration is
required to be included in the calculation of basic and diluted earnings
per share, as if they were outstanding for all periods presented. In
accordance with the SAB 98 requirements, 21,936,981 of the founder's shares
are considered to be nominal issuances and have been considered outstanding
for all of the period ended March 31, 1999.
All outstanding stock options and warrants have been excluded from the
calculation of diluted loss per share, because the assumed conversion of
such instruments is antidilutive.
COMPREHENSIVE INCOME
Statement of Financial Accounting Standards No. 130, "Reporting
Comprehensive Income," establishes standards for the reporting and display
of comprehensive income and its components in a full set of general purpose
financial statements. To date, the Company has not had any transactions
that are required to be reported in comprehensive income.
8
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2000 (CONTINUED)
SEGMENT INFORMATION
The Company has determined that it does not have separately reportable
operating segments in accordance with Statement of Financial Accounting
Standards No. 131, "Disclosures about Segments of an Enterprise and Related
Information".
USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the amounts reported in the financial statements
and accompanying notes. Actual results may differ from those estimates.
3. COMMITMENTS AND CONTINGENCIES
CONDITIONAL LICENSE AGREEMENT
In September 1999, Allen and CytoDyn delivered written notice to the
Company that they believed that the Purchase Agreement is void and is not
enforceable due to fraudulent inducement by Three R and other, unspecified
reasons. Allen and CytoDyn have demanded that Three R and its owners
surrender any and all stock in the Company, which was obtained pursuant to
the Purchase Agreement.
In February 2000, the Company entered into a Conditional License Agreement
with Allen and CytoDyn which preserves the Company's rights to the
Technology in the event Allen is successful in his efforts to rescind the
agreements with Three R and its affiliates discussed above. In
consideration for entering into the Conditional License Agreement, the
Company advanced CytoDyn an additional $50,000 pursuant to the terms of a
Loan Agreement which was previously entered into whereby the Company loaned
CytoDyn $100,000 (See Note 4). At June 30, 2000 and March 31, 2000, the
note receivable of $150,000, which is collateralized by shares of the
Company's stock, plus accrued interest of $10,022 at June 30 and $6,989 at
March 31, was classified as a reduction of shareholders' equity. In
addition, the Company has agreed to continue to pay the obligations due to
Allen under the Purchase Agreement, should Allen prevail in his actions.
MANAGEMENT AGREEMENT
In October 1998, the Company entered into a three year management agreement
for $585,000 per year with Western Center for Clinical Studies, Inc.
("WCCS"), a
9
<PAGE>
AMERIMMUNE PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2000 (CONTINUED)
corporation that is wholly-owned by three of the Company's former officers
and directors. The agreement was scheduled to expire on February 23, 2002.
The management agreement provided for services by WCCS to the Company for
the purpose of assisting the Company in obtaining FDA approval to market
Cytolin(R) for commercial use. In November 1999, the Company notified WCCS
of its rescission of this agreement based upon the Company's belief that
WCCS made certain fraudulent misrepresentations to the Company and had
breached its performance under the management agreement. The Company is
evaluating remedies to collect all amounts paid to WCCS in conjunction with
this agreement.
OFFICER EMPLOYMENT AGREEMENT
During November 1999, the Company hired a new president and chief executive
officer. As of June 30, 2000, the new president and chief executive
officer's employment agreement had not been finalized. Accordingly, based
on preliminary negotiations regarding the employment agreement, the Company
has accrued $70,000 representing the pro rata portion of the expected
compensation applicable to the year ended March 31, 2000, and $45,000
applicable to the three months ended June 30, 2000. Additionally, the
Company expects to issue stock options to the new officer, the terms of
which have not been finalized.
4. RELATED PARTY TRANSACTIONS
During the period from inception (April 10, 1998) through March 31, 2000,
the Company incurred expenses of $442,575 as a result of services performed
by an affiliate, WCCS, on behalf of the Company. In fiscal 1999, the
Company advanced $219,375 to WCCS to commence certain services in
connection with the development of Cytolin(R) to be performed over a three
year period beginning when the management agreement between the parties
became effective. In November 1999, the Company notified WCCS of its
rescission of this agreement and expensed the remaining prepaid management
fees. The Company is evaluating remedies to collect all amounts paid to
WCCS in conjunction with this agreement
During the period from inception (April 10, 1998) through June 30, 2000,
the Company paid consulting fees of $71,319 to Allen for providing
scientific expertise regarding the development of Cytolin(R), $136,875
pursuant to the Patent and Trademark License Agreement, and $25,000 in
consulting fees in connection with the Phase I Testing of Cytolin(R). As
of June 30, 2000, $2,625 of such fees were included in accounts payable.
During the period from inception (April 10, 1998) through March 31, 2000,
the Company incurred legal expenses of $10,000 for an attorney who is also
a director of the Company.
Since inception through January 31, 1999, the Company used part of an
office facility
10
<PAGE>
and administrative services provided by WCCS at no cost. On February 1,
1999, the Company entered into a long-term non-cancellable operating lease
agreement with an unrelated party.
During June 1999, the Company loaned CytoDyn $100,000 to facilitate payment
by CytoDyn of certain legal and office expenses and to facilitate repayment
to the Company by CytoDyn of previous advances. In February 2000, the
Company loaned CytoDyn an additional $50,000 under the same terms and
conditions as the original loan, as consideration for entering into the
Conditional License Agreement (see Note 3). The loans bear interest at a
rate of 8% per annum and are due, together with accrued interest, on or
before February 23, 2001. The loans are secured by 450,000 shares of
Company common stock which are owned by CytoDyn. The Company believes that
these loans are fully collectible.
11
<PAGE>
PART I
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
Some of the statements made in this Form 10-QSB and the documents
incorporated herein by reference that are not historical facts, such as
anticipated results of clinical trials, may constitute "forward-looking
statements," which forward looking statements are made pursuant to the safe
harbor provisions in the federal securities laws. These statements often
can be identified by the use of terms such as "may," "will," "expect,"
"anticipate," "estimate," "should", "could", "experts", "plans",
"believes", "predicts", "potential", or "continue," or the negative
thereof. Such forward-looking statements speak only as of the date made.
Forward-looking statements are subject to risks, uncertainties and other
factors beyond the control of the Company that could cause actual results,
levels of activity, performance, achievements, and events to differ
materially from historical results of operations, levels of activity,
performance, achievements, and events and any future results, levels of
activity, performance, achievements and events implied by such forward-
looking statements. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, the Company
cannot guarantee future results, levels of activity, performance,
achievements, or events. Moreover, neither the Company nor any other
person assumes responsibility for the accuracy or completeness of such
statements. The Company disclaims any obligation to revise any forward-
looking statements to reflect events or circumstances after the date of
such statement or to reflect the occurrence of anticipated or unanticipated
events.
PLAN OF OPERATION
The Company (for purposes of this section, the term the "Company"
includes the predecessor entity to its current operations, British Lion) is
a development stage pharmaceutical research company and has not generated
any revenues from operations for the period from April 10, 1998 (the date
that British Lion commenced operations) through June 30, 2000. The Company
is engaged in the pharmaceutical research business with the primary purpose
of developing Cytolin(R), a drug designed to protect the immune system,
especially in patients suffering from Human Immunodeficiency Virus (HIV).
The Company believes that Cytolin(R) may be an important drug for the
growing number of patients who have not been receiving treatment, for those
who are on multi-drug therapy, and for those who have become resistant to
drugs currently used to treat the HIV/AIDS virus. The Company intends to
seek governmental approval from the Food and Drug Administration ("FDA")
for Cytolin(R). The Company has devoted substantially all of its resources
to the acquisition of a license, research and development of Cytolin(R),
and expenses related to the startup of its business. The Company has been
unprofitable since inception and expects to incur substantial additional
operating losses for the next twelve months, as well as for the next few
years, as it increases expenditures on research and development and
allocates significant and increasing resources to clinical testing,
marketing and other activities.
In November and December 1998, the Company sold 1,426,790 shares of
its common stock (at approximately $0.21 per share), for gross proceeds of
$300,000, to certain accredited investors in a private placement. In
December 1998, the Company
12
<PAGE>
began a second private placement of common stock to accredited investors,
which was completed on February 22, 1999. The second private placement was
made on a minimum/maximum "best efforts" basis. The Company raised the
maximum amount of gross proceeds of $3,210,000 (7,633,364 common shares at
approximately $0.42 per share) and paid cash offering expenses of $159,698.
Net cash proceeds from the private placement aggregated $3,050,302. The
Company believes that the funds received in these private placements will
enable it to satisfy its cash requirements without the need to raise
additional funds before September 30, 2000. The Company has commenced a
tolerability study for Cytolin(R) after a clinical protocol was sanctioned
by the FDA and the bulk drug was manufactured, tested, packaged, and
released for clinical use. The Company has completed the submission of
related manufacturing records to the FDA.
The Company estimates that it will require significant additional
funding over the next three years in order to continue operations and to
successfully complete the FDA approval process for Cytolin(R). The Company
believes that additional funds will be needed to fund operations after
September 30, 2000. There can be no assurances that such additional
capital will be available to the Company on favorable terms, if at all.
The failure of the Company to obtain additional funding if and when
required would have a material adverse effect on the Company's ability to
fulfill its business plan, continue its operations and meet its financial
commitments.
RESULTS OF OPERATIONS
For the three months ended June 30, 2000, the Company incurred
$119,075 in research and development expenses, $169,766 in general and
administrative expenses and earned $12,478 in interest income net of taxes
and other expenses, resulting in a net loss of $276,363. The expenses
incurred during this period relate primarily to commencement of research
activities, regulatory and administrative expenses.
For the three months ended June 30, 1999, the Company has incurred
expenses of $259,533 in research and development expenses, $208,534 in
general and administrative expenses and earned $23,999 in interest income
net of taxes and other expenses, resulting in a net loss of $444,068. The
expenses incurred during this period relate primarily to commencement of
research activities, regulatory and administrative expenses.
For the year ended March 31, 2000, the Company incurred $832,518 in
research and development expenses, $1,168,649 in general and administrative
expenses and earned $78,715 in interest income net of taxes and other
expenses, resulting in a net loss of $1,922,452. The expenses incurred
during this period relate primarily to commencement of research activities,
regulatory and administrative expenses.
From April 10, 1998 to March 31, 1999, the Company incurred $422,293
in research and development expenses, $1,769,311 in general and
administrative expenses and earned $8,947 in interest income net of taxes
and other expenses, resulting in a net loss of $2,182,657 (which included
significant non-cash, general and administrative expenses aggregating
$1,498,500 related primarily to issuance of securities in exchange for
services) for the period ended March 31, 1999. The expenses incurred
during this
13
<PAGE>
period relate primarily to the commencement of business operations, the
acquisition of a license, fundraising activities and merger expenses.
The Company's activities to date are not as broad in depth or scope as
the activities it must undertake in the future, and the Company's
historical operations and financial information are not indicative of its
future operating results or financial condition or its ability to operate
profitably as a commercial enterprise if and when it succeeds in bringing
any product to market.
CAPITAL RESOURCES AND LIQUIDITY
From the commencement of operations on April 10, 1998 to June 30, 2000, the
Company had no operating revenues and incurred net losses of $4,381,472.
At June 30, 2000, the Company had working capital of $677,345. The Company
requires significant capital to conduct the research and development and
preclinical and clinical testing of Cytolin(R) that is necessary in order
to complete the FDA approval process. Management of the Company does not
expect to generate revenue from operations within the next year. The
Company believes that additional funds will be needed to fund operations
after September 30, 2000. There can be no assurance that such additional
capital will be available to the Company on favorable terms, if at all.
The failure of the Company to obtain additional funding if and when
required would have a material adverse effect on the Company's ability to
fulfill its business plan, continue its operations and meet its financial
commitments.
In October 1998, the Company entered into a Patent and Trademark
License Agreement (the "Agreement") with Three R. The Company was granted
an irrevocable, exclusive, worldwide license to use all present and future
patent rights, knowledge and background technology owned by Three R
relating to the product, Cytolin(R). In addition, the Agreement granted
the Company a sublicense to the trademark Cytolin(R). The Agreement was
consummated simultaneously with the Company's acquisition of British Lion.
The Company issued 21,936,981 shares of its common stock at $.001 per share
to Three R upon execution of the Agreement, and the Company also agreed to
assume Three R's obligations to pay Allen $1,350,000, payable monthly over
a fifteen year period, and fees of $10,000 per year for consulting services
under the agreements discussed above between Three R and Mr. Allen. See
Note 3 to Unaudited Consolidated Financial Statements contained in Item 1.
of Part I of this Form 10-QSB for a description of these Agreements and
certain potential disputes. The Company could abandon its patent rights
with no further obligations after minimum payments aggregating $180,000 to
Allen, with one year's notice.
Effect of Inflation and Foreign Currency Exchange
-------------------------------------------------
The Company has not experienced material unfavorable effects on its
results of operations due to currency exchange fluctuations with any
foreign suppliers or material unfavorable effects upon its results of
operations as a result of domestic inflation.
Plant, Equipment and Employees
------------------------------
As of this time, the Company does not expect to make any purchases of
significant plant, facilities or equipment and does not foresee a significant
change in the number of employees.
14
<PAGE>
PART II
ITEM 1. LEGAL PROCEEDINGS
The Company is not a party to any legal proceedings which management
believes are not routine and incidental to its business or which are
material. The Company may in the future be a party to legal proceedings.
See Note 3 to Unaudited Consolidated Financial Statements contained in Item
1. of Part I of this Form 10-QSB for a discussion of certain potential disputes.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
--------
2.1 Agreement and Plan of Merger, dated February 17, 1999, by and
among Versailles Capital Corporation, Amerimmune, Inc. and
British Lion Medical, Inc. (2)
3.1 Amended and Restated Articles of Incorporation.(1)
3.2 Amended and Restated By-Laws.(1)
3.3 Articles of Merger, as filed with the Colorado Secretary of State
on February 23, 1999.(2)
3.4 Articles of Amendment to the Articles of Incorporation.(3)
10.1 Patent and Trademark License Agreement between British Lion
Medical, Inc. and Three R Associates, Inc., dated October 24, 1998.(2)
10.2 Termination, Sale and Shareholder Agreement by and among Three R
Associates, Inc., Allen D. Allen and CytoDyn(R) of New Mexico, Inc.,
dated August 1, 1998. (2)
10.3 Management Agreement between British Lion Medical, Inc. and WCCS,
Inc., dated October 24, 1998. (2)
10.4 Subscription, Share Restriction and Proxy Agreement between
British Lion Medical, Inc. and Allen D. Allen, dated October 23,
1998. (2)
10.5 Versailles Capital Corporation 1998 Omnibus Stock Incentive Plan
as amended and restated through February 23, 1999.(4)
10.6 Conditional License Agreement between Allen D. Allen, CytoDyn of
New Mexico, Inc. and Amerimmune, Inc., dated February 24, 2000.(5)
15
<PAGE>
16.0 Letter on change in certifying accountant. (6)
27 Financial Data Schedule.
--------------------------------------------------------------------------
(1) Incorporated by reference to the Registrant's Registration Statement
on Form 10-SB, Registration No. 0-22865, as filed with the Commission
on July 22, 1997, and amended on Form 10-SB/A-1, filed with the
Commission on February 25, 1998.
(2) Incorporated by reference from the like numbered exhibits filed with
the Registrant's Current Report on Form 8-K, as amended, dated March 10,
1999.
(3) Incorporated by reference from the Registrant's September 30, 1999
Form 10-QSB, dated November 12, 1999.
(4) Incorporated by reference from the Registrant's March 31, 1999 Form 10-KSB.
(5) Incorporated by reference from the Registrant's March 31, 2000 Form 10-KSB.
(6) Incorporated by reference from the like numbered exhibit filed with
the Registrant's Current Report on Form 8-K, dated March 29, 1999.
(b) Reports on Form 8-K
-----------------------
During the three months ended June 30, 2000, the Company filed no
Current Reports on Form 8-K.
16
<PAGE>
SIGNATURES
----------
In accordance with the requirements of the Securities Exchange Act of 1934,
the Registrant has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMERIMMUNE PHARMACEUTICALS, INC.
Signatures Title Date
---------- ----- ----
Chairman of the Board
/s/ O.B Parrish and Director August 11, 2000
-------------------------
O.B. Parrish
/s/ Deborah Garrett Kalof Chief Financial Officer August 11, 2000
-------------------------
Deborah Garrett Kalof, M.B.A., C.P.A.
17
